Mucocutaneous presentations of consultant critical and non-critical cases of admitted COVID-19 patients, outpatients, and vaccine-associated dermatoses: a clinical atlas and a large original study of two general COVID-19 centers from Iran
https://doi.org/10.4081/dr.2023.9473
SUPPLEMENTARY FILE: 84
HTML: 14
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Rapid and proper diagnosis of mucocutaneous presentations of COVID-19 which in many cases are representing internal organ damage is a key way to better approach these patients, and it could be even lifesaving. In this original study, we reported consultant critical and non-critical cases of admitted COVID-19 patients and some interesting outpatient cases for 14 months, and some newly encountered vaccine-associated dermatoses. We presented 121 cases divided into 12 categories; all had full multi-aspects photographs attached as an atlas to a Supplementary File. These categories were:1- Generalized papulopustular eruptions (3 patients), 2- Erythroderma (4 patients), 3- Maculopapular lesions(16 patients), 4- Mucosal lesions (8 patients), 5- Urticarial lesions and angioedema (16 patients), 6- Vascular injuries (22 patients), 7- Vesiculobullous lesions (12 patients), 8- The specific new onset of mucocutaneous presentations or aggravation of any especial previous dermatoses (9 patients), 9- Nail changes (3 patients), 10- Hair loss (2 patients), 11- Non-specific mucocutaneous problems (16 patients) and 12-Vaccine-associated dermatoses (10 patients).In the pandemic, if we countered with extensive mucocutaneous lesions with vascular components or vesiculobullous erosive lesions in association with any cutaneous rash that could be an alarming sign of a probable life-threatening systemic event, we would need to approach them as soon as possible.
Lee DS, Mirmirani P, McCleskey P, Mehrpouya M, Gorouhi F. Cutaneous manifestations of COVID-19: a systematic review and analysis of individual patient-level data. Available at SSRN 3677917. 2020. DOI: https://doi.org/10.2139/ssrn.3677917
Seirafianpour F, Sodagar S, Pour Mohammad A, Panahi P, Mozafarpoor S, Almasi S, et al. Cutaneous manifestations and considerations in COVID‐19 pandemic: A systematic review. Dermatologic therapy. 2020;33(6):e13986. DOI: https://doi.org/10.1111/dth.13986
Najar Nobari N, Seirafianpour F, Mashayekhi F, Goodarzi A. A systematic review on treatment‐related mucocutaneous reactions in COVID‐19 patients. Dermatologic therapy. 2020. DOI: https://doi.org/10.1111/dth.14662
Giuliani F, Gualdi G, Amerio P. Effect of immunosuppressive drugs in Immune‐mediated Inflammatory disease during the Coronavirus pandemic. Dermatologic therapy. 2020;33(6):e14204. DOI: https://doi.org/10.1111/dth.14204
Kasperkiewicz M. COVID-19 outbreak and autoimmune bullous diseases: a systematic review of published cases. Journal of the American Academy of Dermatology. 2021;84(2):563-8. DOI: https://doi.org/10.1016/j.jaad.2020.08.012
Nobari NN, Goodarzi A. Patients with specific skin disorders who are affected by COVID‐19: what do experiences say about management strategies? A systematic review. Dermatologic therapy. 2020:e13867. DOI: https://doi.org/10.1111/dth.13867
Paradisi A, Bugatti L, Sisto T, Filosa G, Amerio PL, Capizzi R. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature. Clinical therapeutics. 2008;30(5):930-40. DOI: https://doi.org/10.1016/j.clinthera.2008.05.014
Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. The Cochrane database of systematic reviews. 2021;2:CD013587-CD. DOI: https://doi.org/10.1002/14651858.CD013587.pub2
Litaiem N, Hajlaoui K, Karray M, Slouma M, Zeglaoui F. Acute generalized exanthematous pustulosis after COVID‐19 treatment with hydroxychloroquine. Dermatologic therapy. 2020. DOI: https://doi.org/10.1111/dth.13565
Balak DM, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckland, NZ). 2017;7:87. DOI: https://doi.org/10.2147/PTT.S126727
Sachdeva M, Mufti A, Maliyar K, Lytvyn Y, Yeung J. Hydroxychloroquine effects on psoriasis: a systematic review and a cautionary note for COVID-19 treatment. Journal of the American Academy of Dermatology. 2020. DOI: https://doi.org/10.1016/j.jaad.2020.05.074
Ramírez E, Urroz M, Rodríguez A, González-Muñoz M, Martín-Vega A, Villán Y, et al. Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data. Frontiers in pharmacology. 2020;11:2024. DOI: https://doi.org/10.3389/fphar.2020.602841
Moradimajd P, Samaee H, Sedigh‐Maroufi S, Kourosh‐Aami M, Mohsenzadagan M. Administration of intravenous immunoglobulin in the treatment of COVID‐19: a review of available evidence. Journal of medical virology. 2020. DOI: https://doi.org/10.1002/jmv.26727
van Paassen J, Vos JS, Hoekstra EM, Neumann KM, Boot PC, Arbous SM. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Critical Care. 2020;24(1):1-22. DOI: https://doi.org/10.1186/s13054-020-03400-9
Alves Batista Morita TC, Tres GFS, Jardim Criado RF, Sotto MN, Criado PR. Update on vasculitis: an overview and dermatological clues for clinical and histopathological diagnosis-part I. ANAIS BRASILEIROS DE DERMATOLOGIA. 2020;95(3):355-71. DOI: https://doi.org/10.1016/j.abd.2020.01.003
Hasan S, Jangra J, Choudhary P, Mishra S. Erythema multiforme: A recent update. Biomedical and Pharmacology Journal. 2018;11(1):167-70. DOI: https://doi.org/10.13005/bpj/1358
Mahajan K, Relhan V, Relhan AK, Garg VK. Pityriasis rosea: An update on etiopathogenesis and management of difficult aspects. Indian journal of dermatology. 2016;61(4):375. DOI: https://doi.org/10.4103/0019-5154.185699
Rebora A. Telogen effluvium: a comprehensive review. Clinical, cosmetic and investigational dermatology. 2019;12:583. DOI: https://doi.org/10.2147/CCID.S200471
Schaefer P. Acute and chronic urticaria: evaluation and treatment. American family physician. 2017;95(11):717-24.
Sadeghzadeh-Bazargan, A., Behrangi, E., Goodarzi, A. Cytokine storm and probable role of immunoregulatory drugs in COVID-19: a comprehensive review. Iranian Journal of Dermatology, 2020; 23(Suppl.1(COVID-19)): 13-18.
Kooranifar S, Sadeghipour A, Riahi T, Goodarzi A, Tabrizi S, Davoody N. Histopathologic survey on lung necropsy specimens of 15 patients who died from COVID-19: A large study from Iran with a high rate of anthracosis. Medical Journal of The Islamic Republic of Iran (MJIRI). 2021;35(1):481-90. DOI: https://doi.org/10.47176/mjiri.35.63
Najar Nobari N, Seirafianpour F, Dodangeh M, Sadeghzadeh‐Bazargan A, Behrangi E, Mozafarpoor S, et al. A systematic review of the histopathologic survey on skin biopsies in patients with Corona Virus Disease 2019 (COVID‐19) who developed virus or drug‐related mucocutaneous manifestations. Experimental dermatology. 2021. DOI: https://doi.org/10.1111/exd.14384
Nobari NN, Montazer F, Seirafianpour F, Goodarzi A. Histopathologic changes and cellular events of organs systems in COVID-19. Journal of Cellular and Molecular Anesthesia. 2021;6(1):81-8.
Sadeghzadeh‐Bazargan A, Rezai M, Nobari NN, Mozafarpoor S, Goodarzi A. Skin manifestations as potential symptoms of diffuse vascular injury in critical COVID‐19 patients. Journal of cutaneous pathology. 2021. DOI: https://doi.org/10.1111/cup.14059
Cabanillas B, Akdis C, Novak N. Allergic reactions to the first COVID‐19 vaccine: a potential role of Polyethylene glycol? : Wiley Online Library; 2020. DOI: https://doi.org/10.1111/all.14711
Falo Jr LD. Advances in skin science enable the development of a COVID-19 vaccine. Journal of the American Academy of Dermatology. 2020. DOI: https://doi.org/10.1016/j.jaad.2020.05.126
Kleine-Tebbe J, Klimek L, Hamelmann E, Pfaar O, Taube C, Wagenmann M, et al. Severe allergic reactions to the COVID-19 vaccine–statement and practical consequences. Allergologie select. 2021;5:26. DOI: https://doi.org/10.5414/ALX02215E
Klimek L, Novak N, Hamelmann E, Werfel T, Wagenmann M, Taube C, et al. Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA. Allergo journal international. 2021;30(2):51-5. DOI: https://doi.org/10.1007/s40629-020-00160-4
Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S, et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines. Allergy.
Atefi N, Behrangi E, Mozafarpoor S, Seirafianpour F, Peighambari S, Goodarzi A. N-acetylcysteine and coronavirus disease 2019: May it work as a beneficial preventive and adjuvant therapy? A comprehensive review study. Journal of Research in Medical Sciences. 2020;25(1):109. DOI: https://doi.org/10.4103/jrms.JRMS_777_20
Goodarzi A. A comprehensive review on COVID-19 infection and comorbidities of various organs. Acta Medica Iranica. 2021:4-14.
Mohamadi M, Goodarzi A, Aryannejad A, Fattahi N, Alizadeh-Khoei M, Miri S, et al. Geriatric challenges in the new coronavirus disease-19 (COVID-19) pandemic: A systematic review. Medical Journal of the Islamic Republic of Iran. 2020;34:123. DOI: https://doi.org/10.47176/mjiri.34.123
Sadeghzadeh-Bazargan A, Behrangi E, Goodarzi A. Systemic retinoids in the COVID-19 era–are they helpful, safe, or harmful? a comprehensive systematized review. Iranian Journal of Dermatology. 2020;23(Suppl. 1 (COVID-19)):9-12.
Seirafianpour F, Mozafarpoor S, Fattahi N, Sadeghzadeh‐Bazargan A, Hanifiha M, Goodarzi A. Treatment of COVID‐19 with pentoxifylline: Could it be a potential adjuvant therapy? Dermatologic Therapy. 2020;33(4):e13733. DOI: https://doi.org/10.1111/dth.13733
Riahi T, Sadeghzadeh-Bazargan A, Shokri S, Ahmadvand D, Hassanlouei B, Baghestani A, et al . The effect of opium on severity of COVID-19 infection:An original study from Iran. Med J Islam Repub Iran. 2021; 35 (1) :870-874. DOI: https://doi.org/10.47176/mjiri.35.115
Kalantari S, Sadeghzadeh-Bazargan A, Ebrahimi S, Yassin Z, Faiz S H R, Kabir A, et al . The effect of influenza vaccine on severity of COVID-19 infection: An original study from Iran. Med J Islam Repub Iran. 2021; 35 (1) :865-869. DOI: https://doi.org/10.47176/mjiri.35.114
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
